Cable Hill Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Cable Hill Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-240	Closed	-$19K	–	404
2019 Q1	$19K	Hold	240	–	–	0.01%	382
2018 Q4	$13K	Hold	240	–	–	0.01%	407
2018 Q3	$11K	Sell	240 -574	-71%	-$27K	﹤0.01%	405
2018 Q2	$34K	Hold	814	–	–	0.01%	248
2018 Q1	$33K	Hold	814	–	–	0.01%	255
2017 Q4	$40K	Sell	814 -174	-18%	-$9.54K	0.02%	270
2017 Q3	$50K	Buy	988 +958	+3,193%	+$50.2K	0.02%	258
2017 Q2	$2K	Hold	30	–	–	﹤0.01%	679
2017 Q1	$1K	Hold	30	–	–	﹤0.01%	712
2016 Q4	$1K	Sell	30 -9	-23%	-$356	﹤0.01%	690
2016 Q3	$1K	Buy	39 +9	+30%	+$282	﹤0.01%	807
2016 Q2	$1K	Buy	+30	New	+$968	﹤0.01%	660
2015 Q3	–	Sell	-113	Closed	-$7K	–	727
2015 Q2	$7K	Sell	113 -84	-43%	-$5.34K	0.01%	523
2015 Q1	$12K	Sell	197 -5	-2%	-$339	0.01%	398
2014 Q4	$12K	Buy	+202	New	+$9.97K	0.01%	395

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cable Hill Partners's IONS Position: Q2 2019 in Review

Cable Hill Partners sold out of Ionis Pharmaceuticals (IONS) in Q2 2019, closing a stake of 240 shares — an estimated $19K sold.

Cable Hill Partners first reported a position in IONS in Q4 2014 and held it in 15 quarters. The position peaked at $50K in Q3 2017. 396 funds tracked by Wall St. Rank hold IONS as of Q2 2019.

Cable Hill Partners reported no remaining Ionis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 240 Ionis Pharmaceuticals shares in Q2 2019, an estimated $19K.
Cable Hill Partners first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 15 quarters.
Cable Hill Partners's Ionis Pharmaceuticals position peaked at $50K in Q3 2017.
396 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.